Liaoning Chengda Biotechnology Co Ltd
SSE:688739

Watchlist Manager
Liaoning Chengda Biotechnology Co Ltd Logo
Liaoning Chengda Biotechnology Co Ltd
SSE:688739
Watchlist
Price: 27.7 CNY -3.65% Market Closed
Market Cap: 5.1B CNY
Have any thoughts about
Liaoning Chengda Biotechnology Co Ltd?
Write Note

Liaoning Chengda Biotechnology Co Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Liaoning Chengda Biotechnology Co Ltd
Cash & Cash Equivalents Peer Comparison

Comparables:
6160
603392
002252
300122
300896

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Liaoning Chengda Biotechnology Co Ltd
SSE:688739
Cash & Cash Equivalents
ÂĄ4.5B
CAGR 3-Years
66%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cash & Cash Equivalents
ÂĄ15B
CAGR 3-Years
33%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cash & Cash Equivalents
ÂĄ3.8B
CAGR 3-Years
75%
CAGR 5-Years
55%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Cash & Cash Equivalents
ÂĄ1.9B
CAGR 3-Years
-1%
CAGR 5-Years
13%
CAGR 10-Years
7%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cash & Cash Equivalents
ÂĄ5.6B
CAGR 3-Years
3%
CAGR 5-Years
82%
CAGR 10-Years
19%
Imeik Technology Development Co Ltd
SZSE:300896
Cash & Cash Equivalents
ÂĄ2.4B
CAGR 3-Years
-11%
CAGR 5-Years
56%
CAGR 10-Years
N/A

See Also

What is Liaoning Chengda Biotechnology Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
4.5B CNY

Based on the financial report for Dec 31, 2023, Liaoning Chengda Biotechnology Co Ltd's Cash & Cash Equivalents amounts to 4.5B CNY.

What is Liaoning Chengda Biotechnology Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
31%

Over the last year, the Cash & Cash Equivalents growth was -22%. The average annual Cash & Cash Equivalents growth rates for Liaoning Chengda Biotechnology Co Ltd have been 66% over the past three years , 31% over the past five years .

Back to Top